Isabel Cervera

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Alberto M. Borobia, Antonio J. Carcas, Mayte Pérez‐Olmeda et al. · The Lancet · 2021 · 384 citations · Full text

The Impact of COVID-19 on the Management of European Protected Areas and Policy Implications

James McGinlay, Vassilis Gkoumas, Jens Holtvoeth et al. · Forests · 2020 · 150 citations · Full text

Community-based Conservation, Covid-19 Epidemiology, Environmental Planning +16

Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals

Daniel Lozano‐Ojalvo, Carmen Cámara, Eduardo López‐Granados et al. · Cell Reports · 2021 · 118 citations · Full text

A 38-kD Mycobacterium tuberculosis antigen associated with infection. Its isolation and serologic evaluation.

Clara Espitia, Isabel Cervera, Ramón A. González et al. · PubMed · 1989 · 91 citations · Full text

Medical Microbiology, Pulmonary Tuberculosis, Tuberculosis Prevention +15

Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR

Megan Schwarz, Denis Torre, Daniel Lozano‐Ojalvo et al. · Nature Biotechnology · 2022 · 44 citations · Full text

Viral Diagnostics, Whole-blood Pcr, Vaccine Target +7